Jan Bultas

3.1k total citations
60 papers, 2.2k citations indexed

About

Jan Bultas is a scholar working on Physiology, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Jan Bultas has authored 60 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 22 papers in Cardiology and Cardiovascular Medicine and 11 papers in Epidemiology. Recurrent topics in Jan Bultas's work include Lysosomal Storage Disorders Research (24 papers), Trypanosoma species research and implications (10 papers) and Glycogen Storage Diseases and Myoclonus (6 papers). Jan Bultas is often cited by papers focused on Lysosomal Storage Disorders Research (24 papers), Trypanosoma species research and implications (10 papers) and Glycogen Storage Diseases and Myoclonus (6 papers). Jan Bultas collaborates with scholars based in Czechia, United States and United Kingdom. Jan Bultas's co-authors include William R. Wilcox, David G. Warnock, Maryam Banikazemi, Aleš Linhart, Debora Karetová, Robert J. Desnick, Seymour Packman, Tomáš Paleček, M. Elleder and J. Ledvinová and has published in prestigious journals such as Annals of Internal Medicine, Journal of the American College of Cardiology and Biochemical and Biophysical Research Communications.

In The Last Decade

Jan Bultas

50 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Bultas Czechia 18 1.9k 1.0k 597 509 426 60 2.2k
Peter F. Bodary United States 20 454 0.2× 451 0.4× 56 0.1× 99 0.2× 54 0.1× 44 1.3k
Cynthia K. Silbert United States 19 267 0.1× 132 0.1× 56 0.1× 329 0.6× 37 0.1× 30 1.3k
Marta Serrano Spain 16 864 0.5× 436 0.4× 28 0.0× 121 0.2× 49 0.1× 28 1.3k
Elisabetta Pasquini Italy 23 232 0.1× 83 0.1× 366 0.6× 88 0.2× 50 0.1× 59 1.4k
Claudia Blasetti Fantauzzi Italy 16 317 0.2× 217 0.2× 50 0.1× 83 0.2× 92 0.2× 17 1.3k
Christoph Busch Germany 15 349 0.2× 113 0.1× 45 0.1× 64 0.1× 38 0.1× 20 1.7k
Chaoshu Tang China 19 337 0.2× 123 0.1× 95 0.2× 92 0.2× 18 0.0× 83 1.5k
James L. Park United States 15 254 0.1× 97 0.1× 63 0.1× 125 0.2× 27 0.1× 19 1.1k
Deborah A. Robins United States 17 629 0.3× 528 0.5× 72 0.1× 97 0.2× 9 0.0× 27 2.7k
Stefan K. Nilsson Sweden 21 443 0.2× 366 0.4× 79 0.1× 174 0.3× 5 0.0× 39 1.9k

Countries citing papers authored by Jan Bultas

Since Specialization
Citations

This map shows the geographic impact of Jan Bultas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Bultas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Bultas more than expected).

Fields of papers citing papers by Jan Bultas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Bultas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Bultas. The network helps show where Jan Bultas may publish in the future.

Co-authorship network of co-authors of Jan Bultas

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Bultas. A scholar is included among the top collaborators of Jan Bultas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Bultas. Jan Bultas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karetová, Debora & Jan Bultas. (2023). Chronic venous disease and cardiovascular disease. 20(1). 17–24.
2.
Banikazemi, Maryam, Jan Bultas, Stephen Waldek, et al.. (2020). Agalsidase-Beta Therapy for Advanced Fabry Disease. Annals of Internal Medicine. 146(2). 1 indexed citations
3.
Karetová, Debora, et al.. (2020). Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?. Vnitřní lékařství. 66(2). 97–103. 7 indexed citations
4.
Charalambous, Charalambos Panayiotou, et al.. (2019). A New Strategy for the Treatment of Atherothrombosis – Inhibition of Inflammation. Physiological Research. 68(Suppl 1). S17–S30. 8 indexed citations
5.
Karetová, Debora & Jan Bultas. (2018). Anticoagulant therapy in the elderly. Vnitřní lékařství. 64(11). 1011–1020. 1 indexed citations
6.
Bultas, Jan & Debora Karetová. (2015). Výběr nemocných k léčbě NOAC - co zohlednit?. Interní medicína pro praxi. 17(3). 118–122. 1 indexed citations
7.
Karetová, Debora & Jan Bultas. (2011). Prevence a léčba tromboembolické nemoci 2011. Interní medicína pro praxi. 13(12). 470–475. 1 indexed citations
8.
Hradec, J, Jan Bultas, & Michael Želı́zko. (2010). Stabilní angina pectoris. Doporučený diagnostický a léčebný postup České kardiologické společnosti. Cor et Vasa. 52(9). 543–561. 2 indexed citations
9.
Kampmann, Christoph, Aleš Linhart, Frank Baehner, et al.. (2008). Onset and progression of the Anderson–Fabry disease related cardiomyopathy. International Journal of Cardiology. 130(3). 367–373. 126 indexed citations
10.
Clarke, Joe T.R., Michael L. West, Jan Bultas, & Raphael Schiffmann. (2007). The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genetics in Medicine. 9(8). 504–509. 33 indexed citations
11.
Karetová, Debora & Jan Bultas. (2006). Rezistence na aspirin - laboratorní odchylka, nebo klinický problém?. Interní medicína pro praxi. 2(2). 49–52.
12.
Paleček, Tomáš, Aleš Linhart, Jean-Claude Lubanda, et al.. (2006). Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease. Heart and Vessels. 21(1). 13–19. 14 indexed citations
13.
Merta, M, Jana Reiterová, J. Ledvinová, et al.. (2006). A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrology Dialysis Transplantation. 22(1). 179–186. 58 indexed citations
14.
Eng, Christine M., Dominique P. Germain, Maryam Banikazemi, et al.. (2006). Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine. 8(9). 539–548. 285 indexed citations
15.
Bultas, Jan, et al.. (2005). Primary prevention of coronary artery disease among middle aged men in Prague: Twenty-year follow-up results. Atherosclerosis. 184(1). 86–93. 15 indexed citations
16.
Vaitkus, Paul T., et al.. (2003). Early heightened inflammation promotes greater left ventricular remodeling following anterior myocardial infarction. Journal of the American College of Cardiology. 41(6). 194–194.
17.
Deanfield, John, Jean-Marie R. Detry, Philippe Sellier, et al.. (2002). Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. Journal of the American College of Cardiology. 40(5). 917–925. 17 indexed citations
18.
Linhart, Aleš, Tomáš Paleček, Jan Bultas, et al.. (2000). New insights in cardiac structural changes in patients with Fabry’s disease. American Heart Journal. 139(6). 1101–1108. 189 indexed citations
19.
Anders, Robert J., Stanford S. Jhee, John J. Sramek, et al.. (1995). Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. The American Journal of Cardiology. 75(16). 1102–1106. 35 indexed citations
20.
Jíndra, A, et al.. (1991). Investigation of human and rat inactive renin in plasma and kidney. Canadian Journal of Physiology and Pharmacology. 69(9). 1341–1349. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter F. Bodary Breakdown of academic impact, for papers by Cynthia K. Silbert Breakdown of academic impact, for papers by Marta Serrano Breakdown of academic impact, for papers by Elisabetta Pasquini Breakdown of academic impact, for papers by Claudia Blasetti Fantauzzi Breakdown of academic impact, for papers by Christoph Busch Breakdown of academic impact, for papers by Chaoshu Tang Breakdown of academic impact, for papers by James L. Park Breakdown of academic impact, for papers by Deborah A. Robins Breakdown of academic impact, for papers by Stefan K. Nilsson
Rankless by CCL
2026